Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
The median length of survival for individuals with ILD who completed pulmonary rehabilitation was 6.1 years vs 4.7 years in the control group. Pulmonary rehabilitation (PR) may improve survival at 5 ...
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
The following is a summary of “Diagnosis, screening, and follow-up of patients with familial interstitial lung disease: ...
Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
"We are thrilled to welcome Dr. Kokoszynska to our team," said Patrick A. Taylor, York Hospital president and CEO. "Her ...
Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback